Clinical Trials Browser

Phase 3 × tremelimumab × Dermatologic × Clear all

NCT00257205 2012-07-02

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Phase 3 Completed

Melanoma